Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2015

Published: Mar, 2015 | Pages: 302 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2015’, provides an overview of the Graft Versus Host Disease (GVHD)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (GVHD)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Graft Versus Host Disease (GVHD) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Graft Versus Host Disease (GVHD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Graft Versus Host Disease (GVHD) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Graft Versus Host Disease (GVHD)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Graft Versus Host Disease (GVHD) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Graft Versus Host Disease (GVHD) Overview 10
Therapeutics Development 11
Pipeline Products for Graft Versus Host Disease (GVHD) - Overview 11
Pipeline Products for Graft Versus Host Disease (GVHD) - Comparative Analysis 12
Graft Versus Host Disease (GVHD) - Therapeutics under Development by Companies 13
Graft Versus Host Disease (GVHD) - Therapeutics under Investigation by Universities/Institutes 18
Graft Versus Host Disease (GVHD) - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Unknown Stage Products 22
Graft Versus Host Disease (GVHD) - Products under Development by Companies 23
Graft Versus Host Disease (GVHD) - Products under Investigation by Universities/Institutes 27
Graft Versus Host Disease (GVHD) - Companies Involved in Therapeutics Development 28
AbGenomics International, Inc. 28
Adienne Pharma & Biotech 29
Alder Biopharmaceuticals Inc. 30
Alexion Pharmaceuticals, Inc. 31
Apceth GmbH & Co. KG 32
Athersys, Inc. 33
Bellicum Pharmaceuticals, Inc. 34
Biogen Idec Inc. 35
Dr. Falk Pharma GmbH 36
Enlivex Therapeutics Ltd 37
Escape Therapeutics, Inc. 38
F. Hoffmann-La Roche Ltd. 39
Generon (Shanghai) Corporation Ltd. 40
Idera Pharmaceuticals, Inc. 41
ImmuNext, Inc. 42
Immunomedics, Inc. 43
Jazz Pharmaceuticals plc 44
Kadmon Corporation, LLC 45
Kamada Ltd. 46
Kymab Limited 47
Lycera Corp. 48
Mesoblast Limited 49
Millennium Pharmaceuticals, Inc. 50
MSM Protein Technologies, Inc. 51
Neopharm Ltd. 52
NeoStem, Inc. 53
Novartis AG 54
Omni Bio Pharmaceutical Inc. 55
Pharmacyclics, Inc. 56
Pharmicell Co., Ltd. 57
Pluristem Therapeutics Inc. 58
R-Tech Ueno, Ltd. 59
REGiMMUNE Corporation 60
Rigel Pharmaceuticals, Inc. 61
Sarepta Therapeutics, Inc. 62
Seattle Genetics, Inc. 63
Sigmoid Pharma Limited 64
Soligenix, Inc. 65
Spherium Biomed S.L. 66
Targazyme, Inc. 67
Therapix Biosciences Ltd 68
Tobira Therapeutics, Inc. 69
Xenikos B.V. 70
Graft Versus Host Disease (GVHD) - Therapeutics Assessment 71
Assessment by Monotherapy Products 71
Assessment by Combination Products 72
Assessment by Target 73
Assessment by Mechanism of Action 76
Assessment by Route of Administration 79
Assessment by Molecule Type 81
Drug Profiles 83
AbGn-168H - Drug Profile 83
aldesleukin - Drug Profile 85
Alecmestencel-L - Drug Profile 87
Alpha-1 Antitrypsin - Drug Profile 88
alpha-1 proteinase inhibitor (human) - Drug Profile 89
ALXN-1007 - Drug Profile 91
anti-thymocyte globulin (rabbit) - Drug Profile 92
Antibodies to Antagonize CD40L for Autoimmune Diseases and GVHD - Drug Profile 94
Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease - Drug Profile 95
ApoCell - Drug Profile 96
beclomethasone dipropionate - Drug Profile 97
begelomab - Drug Profile 99
bortezomib - Drug Profile 100
BPX-501 - Drug Profile 105
brentuximab vedotin - Drug Profile 107
budesonide - Drug Profile 112
Bz-423 - Drug Profile 115
cannabidiol - Drug Profile 116
Cell Therapy for Autoimmune Diseases and GVHD - Drug Profile 117
Cell Therapy for CNS, Respiratory, Immunology and Metabolic Disorders - Drug Profile 119
Cell Therapy for Graft Versus Host Disease - Drug Profile 120
Cell Therapy for Graft Versus Host Disease - Drug Profile 121
Cell Therapy for Graft Versus Host Disease - Drug Profile 122
Cell Therapy for Graft versus Host Disease - Drug Profile 123
Cell Therapy for Graft-Versus Host Disease - Drug Profile 124
Cell Therapy for GVHD - Drug Profile 125
cenicriviroc mesylate - Drug Profile 126
Cerecellgram for Graft Versus Host Disease - Drug Profile 128
clazakizumab - Drug Profile 129
Coversin - Drug Profile 131
cyclosporine IR + cyclosporine CR - Drug Profile 132
defibrotide - Drug Profile 133
Drugs for Acute and Chronic GVHD - Drug Profile 136
Drugs for Graft Versus Host Disease - Drug Profile 137
erismodegib - Drug Profile 138
F-652 - Drug Profile 141
Fc-Alpha-1 Antitrypsin - Drug Profile 142
FcAAT-2 - Drug Profile 143
FcAAT-3 - Drug Profile 144
Ha-7 - Drug Profile 145
ibrutinib - Drug Profile 146
ImmuneSafe - Drug Profile 152
ImmuStem - Drug Profile 153
IMO-8400 - Drug Profile 154
inolimomab - Drug Profile 156
IT-603 - Drug Profile 157
IT-901 - Drug Profile 158
KD-025 - Drug Profile 159
KY-1005 - Drug Profile 161
milatuzumab - Drug Profile 162
Monoclonal Antibody to Inhibit CD3 for Autoimmune Disorders, CNS Disorders, Infectious Diseases, Liver Diseases, Metabolic Disorders and Cardiovascular Diseases - Drug Profile 164
MSM-707 - Drug Profile 166
MultiStem - Drug Profile 167
natalizumab - Drug Profile 170
Oligonucleotide to Inhibit NFAT1 for GVHD - Drug Profile 172
panobinostat - Drug Profile 173
PLX-RAD - Drug Profile 179
Protein to Activate TLR5 for Infectious Disease and GVHD - Drug Profile 182
Recombinant HIV Gp120 Protein for GvHD And Autoimmune Disorders - Drug Profile 183
Recombinant Protein to Inhibit ILT3 for Graft Versus Host Disease - Drug Profile 184
remestemcel-L - Drug Profile 185
RGI-2001 - Drug Profile 188
RO-2959 - Drug Profile 190
Small Molecule for Graft Versus Host Disease, Hemophagocytic Lymphohistiocytosis and Autoimmune Disorders - Drug Profile 191
Small Molecule to Inhibit Protein Kinase C Theta for Autoimmune Disorder - Drug Profile 192
Small Molecules to Activate Telomerase for ALS, GVHD, Ageing and Leukemia - Drug Profile 193
Small Molecules to Inhibit SHIP1 for Oncology and Immunology - Drug Profile 194
SP-12008 - Drug Profile 195
T-Guard - Drug Profile 196
TZ-101 - Drug Profile 198
Graft Versus Host Disease (GVHD) - Recent Pipeline Updates 200
Graft Versus Host Disease (GVHD) - Dormant Projects 283
Graft Versus Host Disease (GVHD) - Discontinued Products 287
Graft Versus Host Disease (GVHD) - Product Development Milestones 288
Featured News & Press Releases 288
Appendix 296
Methodology 296
Coverage 296
Secondary Research 296
Primary Research 296
Expert Panel Validation 296
Contact Us 296
Disclaimer 297

List of Tables

Number of Products under Development for Graft Versus Host Disease (GVHD), H1 2015 16
Number of Products under Development for Graft Versus Host Disease (GVHD) - Comparative Analysis, H1 2015 17
Number of Products under Development by Companies, H1 2015 19
Number of Products under Development by Companies, H1 2015 (Contd..1) 20
Number of Products under Development by Companies, H1 2015 (Contd..2) 21
Number of Products under Development by Companies, H1 2015 (Contd..3) 22
Number of Products under Investigation by Universities/Institutes, H1 2015 23
Comparative Analysis by Late Stage Development, H1 2015 24
Comparative Analysis by Clinical Stage Development, H1 2015 25
Comparative Analysis by Early Stage Development, H1 2015 26
Comparative Analysis by Unknown Stage Development, H1 2015 27
Products under Development by Companies, H1 2015 28
Products under Development by Companies, H1 2015 (Contd..1) 29
Products under Development by Companies, H1 2015 (Contd..2) 30
Products under Development by Companies, H1 2015 (Contd..3) 31
Products under Investigation by Universities/Institutes, H1 2015 32
Graft Versus Host Disease (GVHD) - Pipeline by AbGenomics International, Inc., H1 2015 33
Graft Versus Host Disease (GVHD) - Pipeline by Adienne Pharma & Biotech, H1 2015 34
Graft Versus Host Disease (GVHD) - Pipeline by Alder Biopharmaceuticals Inc., H1 2015 35
Graft Versus Host Disease (GVHD) - Pipeline by Alexion Pharmaceuticals, Inc., H1 2015 36
Graft Versus Host Disease (GVHD) - Pipeline by Apceth GmbH & Co. KG, H1 2015 37
Graft Versus Host Disease (GVHD) - Pipeline by Athersys, Inc., H1 2015 38
Graft Versus Host Disease (GVHD) - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2015 39
Graft Versus Host Disease (GVHD) - Pipeline by Biogen Idec Inc., H1 2015 40
Graft Versus Host Disease (GVHD) - Pipeline by Dr. Falk Pharma GmbH, H1 2015 41
Graft Versus Host Disease (GVHD) - Pipeline by Enlivex Therapeutics Ltd, H1 2015 42
Graft Versus Host Disease (GVHD) - Pipeline by Escape Therapeutics, Inc., H1 2015 43
Graft Versus Host Disease (GVHD) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 44
Graft Versus Host Disease (GVHD) - Pipeline by Generon (Shanghai) Corporation Ltd., H1 2015 45
Graft Versus Host Disease (GVHD) - Pipeline by Idera Pharmaceuticals, Inc., H1 2015 46
Graft Versus Host Disease (GVHD) - Pipeline by ImmuNext, Inc., H1 2015 47
Graft Versus Host Disease (GVHD) - Pipeline by Immunomedics, Inc., H1 2015 48
Graft Versus Host Disease (GVHD) - Pipeline by Jazz Pharmaceuticals plc, H1 2015 49
Graft Versus Host Disease (GVHD) - Pipeline by Kadmon Corporation, LLC, H1 2015 50
Graft Versus Host Disease (GVHD) - Pipeline by Kamada Ltd., H1 2015 51
Graft Versus Host Disease (GVHD) - Pipeline by Kymab Limited, H1 2015 52
Graft Versus Host Disease (GVHD) - Pipeline by Lycera Corp., H1 2015 53
Graft Versus Host Disease (GVHD) - Pipeline by Mesoblast Limited, H1 2015 54
Graft Versus Host Disease (GVHD) - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 55
Graft Versus Host Disease (GVHD) - Pipeline by MSM Protein Technologies, Inc., H1 2015 56
Graft Versus Host Disease (GVHD) - Pipeline by Neopharm Ltd., H1 2015 57
Graft Versus Host Disease (GVHD) - Pipeline by NeoStem, Inc., H1 2015 58
Graft Versus Host Disease (GVHD) - Pipeline by Novartis AG, H1 2015 59
Graft Versus Host Disease (GVHD) - Pipeline by Omni Bio Pharmaceutical Inc., H1 2015 60
Graft Versus Host Disease (GVHD) - Pipeline by Pharmacyclics, Inc., H1 2015 61
Graft Versus Host Disease (GVHD) - Pipeline by Pharmicell Co., Ltd., H1 2015 62
Graft Versus Host Disease (GVHD) - Pipeline by Pluristem Therapeutics Inc., H1 2015 63
Graft Versus Host Disease (GVHD) - Pipeline by R-Tech Ueno, Ltd., H1 2015 64
Graft Versus Host Disease (GVHD) - Pipeline by REGiMMUNE Corporation, H1 2015 65
Graft Versus Host Disease (GVHD) - Pipeline by Rigel Pharmaceuticals, Inc., H1 2015 66
Graft Versus Host Disease (GVHD) - Pipeline by Sarepta Therapeutics, Inc., H1 2015 67
Graft Versus Host Disease (GVHD) - Pipeline by Seattle Genetics, Inc., H1 2015 68
Graft Versus Host Disease (GVHD) - Pipeline by Sigmoid Pharma Limited, H1 2015 69
Graft Versus Host Disease (GVHD) - Pipeline by Soligenix, Inc., H1 2015 70
Graft Versus Host Disease (GVHD) - Pipeline by Spherium Biomed S.L., H1 2015 71
Graft Versus Host Disease (GVHD) - Pipeline by Targazyme, Inc., H1 2015 72
Graft Versus Host Disease (GVHD) - Pipeline by Therapix Biosciences Ltd, H1 2015 73
Graft Versus Host Disease (GVHD) - Pipeline by Tobira Therapeutics, Inc., H1 2015 74
Graft Versus Host Disease (GVHD) - Pipeline by Xenikos B.V., H1 2015 75
Assessment by Monotherapy Products, H1 2015 76
Assessment by Combination Products, H1 2015 77
Number of Products by Stage and Target, H1 2015 79
Number of Products by Stage and Mechanism of Action, H1 2015 82
Number of Products by Stage and Route of Administration, H1 2015 85
Number of Products by Stage and Molecule Type, H1 2015 87
Graft Versus Host Disease (GVHD) Therapeutics - Recent Pipeline Updates, H1 2015 205
Graft Versus Host Disease (GVHD) - Dormant Projects, H1 2015 288
Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..1), H1 2015 289
Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..2), H1 2015 290
Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..3), H1 2015 291
Graft Versus Host Disease (GVHD) - Discontinued Products, H1 2015 292